I agree with many posts that company has failed so far in producing any good results but if you the look into the past 4-5 months activities of the company then you will notice that something big is about to come (It takes on an average 10 years even for a big pharmaceutical company to make a drug). I know you might argue that they even did not get IND approval what they will do. But remember that they have limited resources as far as man power, money goes. You also have to remember that if they are successful, even in one product, then share price will sky rocket. You can retire tomorrow if that happens. So have some trust.
Note: if Regen is successful then BMSN is successful.
I will also say that it is your money, play safe, do whatever is best for you. I am not one to suggest you do anything which you do not like or your conscious does not permit. You might have your family you need support or you might be a student with a lots of student loan or you might be at the retirement stage etc. I do not know what stage you are in but DO WHATEVER YOUR CONCIOUS ASKS YOU TO DO. This is all my opinion and analysis regarding this company.
Here are the facts I have collected for the company, apprx in last 6 monts:
• Oct 08, 2014 - IND application for dCellVax filed
• Oct 15, 2014 - Dr. Amit Patel joins as Scientific Advisory Board. I know person like him will not like to lose his credibility for the sake of money. If Regen fails then it will be a black spot on his carrier also. Investors will blame this person also for the failure. He might have seen something in the product and that is why he has affiliated himself with Regen.
• Oct 28, 2014 - Ebola treatment announcement. Dr Patel might have suggested this.
• Nov 04, 2014 - FDA issues IND Number for dCellVax
• Nov 25, 2014 - Acquired Stem cell intellectual property rights from university of Toronto
• Dec11, 2014 - Presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. As per my thoughts it is a big event.
• Jan 14, 2015 - Employment agreement with Thomas Ichim (Chief Scientific Officer) & Christine Ichim (Director of Molecular Therapeutics). I do not think that these scientists will hamper with their carrier if they do not see anything in the company.
• Feb 17, 2015 - Hired Todd Caven as CFO. Also Koos became CEO with salary. Todd has done his MBA from one of the top MBA schools in the world. He will also not hamper with his carrier.
• Feb 18, 2015 - Bonus shares issued
Note : There might be some typo in the dates but I have tried my level best to be accurate. These dates are from SEC filings.
